daratumumab

Showing 5 posts of 5 posts found.

janssen_latest_logo_on_sign

Genmab receives milestone payment for first Darzalex sale in Europe

May 31, 2016
Manufacturing and Production, Sales and Marketing EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales

Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its …

clinical_trial_3

Darzalex meets endpoint in late-stage multiple myeloma trial

May 19, 2016
Research and Development Genmab, Janssen, daratumumab, darzalex, dexamethasone, lenalidomide, phase 3, phase III, trial

Genmab has announced that positive results from a Phase III trial evaluating Darzalex (daratumumab), which is being developed in partnership …

genmab

Genmab Darzalex success triggers second milestone payment

March 10, 2016
Research and Development, Sales and Marketing Genmab, Janssen, daratumumab, darzalex, follicular lymphoma

Genmab says it has reached a $5 million milestone in its daratumumab collaboration with Janssen as a result of success …

janssen_stairs

Janssen submits EMA application for myeloma drug

September 14, 2015
Sales and Marketing Janssen, daratumumab, multiple myeloma

Janssen has submitted a new marketing authorisation application for European approval of daratumumab for the treatment of patients with relapsed …

Priority review for Novartis myeloma drug

November 26, 2014
Sales and Marketing FDA, Farydak, Novartis, daratumumab, elotuzumab, myeloma, odac

Novartis’ multiple myeloma treatment Farydak has been given an extended review by the FDA after its future seemed in jeopardy …

The Gateway to Local Adoption Series

Latest content